PharmAla Biotech Holdings Inc. focuses on the research and manufacturing of active pharmaceutical ingredients in the healthcare sector. The company shows strong gross margins at 66.0%, indicating effective cost management, but faces significant concerns with negative EBITDA and net margins of -94.1% and -97.4%, respectively, reflecting ongoing operational challenges. Additionally, while the current ratio of 1.17 suggests adequate liquidity, the quick ratio of 0.64 raises some caution regarding immediate financial obligations. Overall, the high margins juxtaposed with poor profitability metrics highlight a need for improved operational efficiency.
Loading financial metrics...
Company has $94K in cash but burned $242K last quarter. At this burn rate, only 0.4 quarters of runway remain without additional financing.
Company posted a loss of $-1.6M over the last year, representing 126.9% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $969K over the last year.
Exceptional revenue growth of 220.6% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 39.9 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 430.0pp, demonstrating strong operational leverage.
Both gross margin (+39.9pp) and operating margin (+430.0pp) are expanding simultaneously, indicating the company is scaling profitably.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (May 31, 2026)